“Compared to the pre-COVID period, the odds ratio for CVD encounters was nearly doubled in each post-COVID period from 31 to 90 days post onset,” Brian Agan, MD, deputy science director and HIV research director of the Infectious Disease Clinical Research Program at USU/HJF and presenting author, told Contagion®.
Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.
Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.
The companies will be seeking emergency authorization for a lighter-dose mRNA vaccine for children aged 5 to <12 years old.
Data finds low risk for anaphylaxis, myocarditis, and other potential complications.
The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.
England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.
The protective effect remained strong through the 18- and 24-month follow-up periods, the study authors said.
Extended findings from blinded mRNA-1273 vaccine pivotal trial include efficacy across subgroups, including elderly and with coexisting conditions.
Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.
The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.
Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.
The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.
A CDC examination of a Delta outbreak in a Texas prison showed unvaccinated persons have higher attack rates, hospitalizations, and deaths, but vaccinated persons can still contract and spread the virus.
A third dose booster vaccination given to persons 60 years of age or over in Israel was confirmed to lower their rate of COVID-19 infection compared to a 2-dose regimen.
New research shows COVID-19 mortality risk to be more nuanced than previous studies.
A presentation of available third-dose data suggest the adverse event rate is consistent with that observed with second doses.
With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.
To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.
Patients with cancer now have official confirmation that vaccinating against COVID-19 will protect them from contracting the virus.
With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.
After two doses of the Pfizer-BioNTech COVID-19 vaccine, 83% of allogeneic hematopoietic stem cell transplant recipients showed positive antibody response.
Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.
The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.
Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.
The data, which reflects pre-pandemic routine vaccination levels, showed human papillomavirus vaccine rates increased among teens ages 13-17.
A smaller dosage was used and with their results the two companies plan to submit their data to governmental regulatory agencies around the world.
The Centers for Disease Control and Prevention's (CDC) VISION Network of health care systems provided data for test-negative design analysis of vaccine effectiveness in preventing COVID-19 acute admissions.
After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.
The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.
